何玉先，1966年生，籍貫安徽蕭縣，病毒學(xué)家，病原生物學(xué)研究所研究員，博士生導(dǎo)師。1990-1993年在中國預(yù)防醫(yī)學(xué)科學(xué)院勞動衛(wèi)生與職業(yè)病學(xué)專業(yè)攻讀碩士學(xué)位，從事矽肺致病機制及治療研究。2005-2007年在德國烏爾姆大學(xué)醫(yī)學(xué)病毒學(xué)專業(yè)攻讀博士學(xué)位，從事艾滋病分子病毒學(xué)研究。1997-2008年曾任職美國洛克菲勒大學(xué)訪問學(xué)者、紐約大學(xué)博士后研究員和紐約血液中心助理研究員，主要研究艾滋病及新發(fā)重大傳染病研究。2008年4月回國任職病原生物學(xué)研究所研究員。

艾滋病病毒感染機制、抗病毒藥物及基因治療策略，新型冠狀病毒膜融合的分子機制及強效抑制劑研發(fā)

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

1. Xue J#*, Chong H#, Zhu Y#, Zhang J, Tong L, Lu J, Chen T, Cong Z, Wei Q, He Y*. 2022. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell. 185(1): 131-44. (IF=66.850)

2. Zhu Y#, Dong X#, Liu N, Wu T, Chong H, Lei X, Ren L, Wang J*, He Y*. 2022. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. Emerg Microbes Infect. 11(1):1819-27. (IF=19.568)

3. Chen Y, Jin H*, Tang X, Li L, Geng X, Zhu Y, Chong H, He Y*. 2022. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect. 11(1):30-49. (IF=19.568)

4. Zhu Y#, Yu D#, Hu Y#, Wu T, Chong H, He Y*. 2021. SARS-CoV-2 derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther. 6(1):294. (IF=19.568)

5. Yu D#, Zhu Y#, Jiao T#, Wu T#, Xiao X, Qin B, Hu Y, Chong H, Lei X, Ren L, Cui S*, Wang J*, He Y*. 2021. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect. 10(1):1227-40. (IF=7.163)

6. Yu D#, Zhu Y#, Yan H#, Wu T, Chong H, He Y*. 2021. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 10(1):810-21. (IF=7.163)

7. Jin H, Tang X, Li L, Chen Y, Zhu Y, Chong H, He Y*. 2021. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol. 18(3): 660-74. (IF=11.530)

8. Zhu Y#, Yu D#, Han Y#, Yan H, Chong H, Ren L, Wang J*, Li T*, He Y*. 2020. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv. 6(45): eabc9999. (IF=14.136)

9. Chong H#, Xue J#, Zhu Y#, Cong Z, Chen T, Wei Q, Qin C*, He Y*. 2019. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog. 15(2):e1007552. (IF=6.463)

10. He Y*, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q*. 2008. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci USA. 105(42):16332-7. (IF=9.380)